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Abstract
Background and Aim Aspirin is a commonly used over-
the-counter (OTC) agent for the symptomatic treatment of
acute pain, fever, or the common cold, but data regarding
safety in this context are limited. In order to characterize
the safety of aspirin beyond single-dose or long-term use
data, we conducted a meta-analysis of multiple-dose,
multiple-day studies of OTC aspirin at a label-approved
dosage.
Methods We conducted a meta-analysis of individual
patient data from three Bayer-sponsored studies. The meta-
analysis was performed in 2015; the individual studies
were conducted between 2008 and 2012 and were of a
randomized, parallel-group, placebo-controlled design.
Patients received a minimum dosage of aspirin of
2000 mg/day over at least 3 days. The endpoints were
patient-reported adverse events (AEs) with an emphasis on
the system organ class gastrointestinal system. Event
incidences were estimated and an analysis of the odds
ratios (ORs) and risk differences (RDs) of aspirin versus
placebo were performed.
Results Of the 819 patients included, 433 were treated with
aspirin and 386 were treated with placebo. The majority of
patients (85.7 %) received a median dose of aspirin of
3000 mg/day for 3 days. The incidence of the overall AEs
was low and rates were comparable between the aspirin
(10.9 %) and placebo (12.4 %) groups [OR: 0.86 (95 %
confidence interval [CI] 0.56, 1.34); RD: -1.49 (95 % CI
-6.01, 3.03)]. Gastrointestinal AEs were more common in
subjects treated with aspirin (7.4 %) than with placebo
(5.4 %), and although this difference did not reach statis-
tical significance, a trend towards increased risk was
observed with aspirin use [OR: 1.41 (95 % CI 0.78, 2.54);
RD: 2.00 (95 % CI -1.35, 5.35)]. Nausea, upper abdomi-
nal pain, dyspepsia, and diarrhea were the most frequently
reported gastrointestinal AEs. There were no reports of
serious gastrointestinal complications such as bleeding,
perforation, or ulceration.
Conclusions The multiple-dose regimen of aspirin used for
several days according to the OTC label is well-tolerated
by otherwise healthy non-elderly subjects for short-term
and symptomatic treatment of pain, fever, and the common
cold. There were no reports of serious gastrointestinal
complications in either of the groups.
Key Points
The overall incidence of adverse events (AEs) was
low with multiple-dose aspirin used for several days
(10.9 %), with rates comparable with those of
placebo (12.4 %).
A trend towards an increased risk of gastrointestinal
AEs was observed with aspirin relative to placebo,
with incidences of 7.4 and 5.4 %, respectively.
There were no reports of serious gastrointestinal
complications such as bleeding, perforation, or
ulceration.
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1 Background
Aspirin (acetylsalicylic acid) is one of the most commonly
used over-the-counter (OTC) drugs in the world, and is
used for acute self-treatment of symptoms of pain, fever, or
the common cold [1–3]. The recommended OTC dose for
these indications is generally 500–1000 mg repeated at 4-
to 8-h intervals, and is not to exceed 3000 or 4000 mg/day,
depending on country regulations. Treatment in this setting
is typically short-term (mostly 3–5 days), with the exact
duration of therapy dependent on local country regulations
and the indication.
At OTC analgesic doses, aspirin behaves as a traditional
non-selective non-steroidal anti-inflammatory drug
(NSAID), in that it inhibits both cyclo-oxygenase (COX)-1
and COX-2 enzymes [4]. This non-selective COX inhibi-
tion is tied to many of the adverse events (AEs) commonly
associated with this class of medication. Serious gastroin-
testinal complications such as perforations, ulcers, or
bleeding have rarely been reported with short-term or
single-dose studies using OTC doses of aspirin [5, 6].
However, more minor gastrointestinal complaints (i.e.,
dyspepsia) are also of concern, as their occurrence often
leads to avoidance of appropriate treatment by the patient.
Data characterizing the safety profile of OTC aspirin
when used within recommended dose and short-term
duration parameters are quite limited. Observational stud-
ies may not distinguish between short- and long-term OTC
use, may not specify the exact doses administered, and in
some cases OTC data are not captured at all. This dis-
crepancy is important when considering differences
regarding the indication, duration of therapy, and popula-
tion taking prescription or long-term OTC drugs versus
short-term OTC use. As a result, the increased risk of
ulcers, bleeding, perforations, or other serious gastroin-
testinal complications associated with long-term NSAID
use may not accurately represent the magnitude of risk
when these drugs are used as directed in the OTC setting.
This notion is supported by limited data, existing largely
in the form of single-dose and very short-term use studies
[5–8]. In performing the current meta-analysis we sought to
characterize the safety and tolerability of multiple high
OTC doses of aspirin, used over several days for the
symptomatic treatment of acute pain, fever, or the common
cold.
2 Methods
We conducted a descriptive, integrated safety meta-analysis
utilizing individual patient data obtained from Bayer AG
(Leverkusen, Germany)-sponsored studies conducted to
May 2015, in which aspirin was evaluated in a clinical trial
setting and adequate documentation of AE reporting was
available. Studies qualified for analysis if they met the fol-
lowing criteria: (1) contained a treatment arm with patients
receiving aspirin monotherapy at doses C2000 mg/day for
C3 days; and (2) were conducted in a randomized, placebo-
controlled, parallel-group design. Of 87 clinical trials iden-
tified within the Bayer study data pool and conducted
between 1987 and 2012, three satisfied all requirements and
were included in the safety analysis. All three studies were
designed with active and placebo comparators, and two
contained an aspirin plus pseudoephedrine arm. However,
only the aspirinmonotherapy and placebo arms of each study
were evaluated. Details of the aspirin treatment regimens
administered in each study are shown in Table 1. In general,
daily doses of aspirin were between 1000 and 3000 mg for a
duration of 3–5 days.
The endpoints of interest were patient-reported AEs.
AEs of interest were chosen based on previous knowledge
of the safety profile of aspirin and NSAID class-specific
AEs. Medical Dictionary for Regulatory Activities
(MedDRA) codes (version 18.0) were used to identify
these events within the data pool according to either
standardized MedDRA queries (SMQs) or selected
MedDRA preferred terms (PTs), high-level terms
(HLTs), high-level group terms (HLGTs), or system organ
classes (SOCs). Of the AEs, the gastrointestinal SOC and
its related PTs, the combination of the gastrointestinal
disorders heartburn, nausea, vomiting, and abdominal pain
was of major interest for this analysis because their
occurrence often leads to avoidance of appropriate treat-
ment by the patient. Another area of interest was the
serious events gastrointestinal hemorrhage, gastrointesti-
nal ulceration, and gastrointestinal perforation.
Data management and statistical evaluation were per-
formed using the SAS software package version 9.3 (SAS
Institute, Cary, NC, USA). The target SAS database
structure was based on agreement between Bayer AG
(Leverkusen, Germany) and the M.A.R.C.O. Institute for
Clinical Research and Statistics (Du¨sseldorf, Germany).
Bayer provided SAS datasets for the studies, which were
transformed into the target database structure using SAS
modification programs. Information derived from the clini-
cal study reports and listings (i.e., study title, design, blind-
ing, randomization, dosing, AE reporting) was integrated
into the target database. Quality control checks were in place
at each data management step. Checks included double data
entry and standard validation of statistical programs and data
entry including review by a second programmer. The sta-
tistical analysis was exploratory in nature and based on
available data.
Estimated incidence rates were presented for overall
AEs, SOCs, and PTs, and events within each of these
categories were categorized by intensity (mild, moderate,
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severe) for both the aspirin and placebo groups. An anal-
ysis of odds ratios (ORs) and risk differences (RDs) of
aspirin versus placebo was performed.
3 Results
The data pool used for the meta-analysis consisted of a
total of 819 subjects; 433 subjects received aspirin, 386
received placebo. All studies were multiple-dose studies
evaluating the efficacy of aspirin versus placebo in the
short-term treatment of sore throat, headache, or lower
back pain. An overview of the individual study character-
istics is provided in Table 1.
Patient-reported AEs of the individuals included in the
studies were analyzed. The current study compared the
safety of aspirin monotherapy versus placebo and, there-
fore, although the individual studies were each designed
with active and placebo comparators, only the aspirin
monotherapy and placebo arms were included in the meta-
analysis. Subject demographics for both meta-analysis
treatment groups are described in further detail in Table 2.
With the exception of age and sex, baseline characteristics
were generally comparable between the groups. The
majority of patients in the aspirin group received a median
dose of 3000 mg/day for 3 days (n = 372; 86 %). The
remaining patients (n = 62; 14 %) received 2500 or
3000 mg/day for 4–6 days. The duration of aspirin expo-
sure was greatest for the low back pain study (up to 6 days)
compared with 3 or 4 days for sore throat and headache.
The overall median total exposure to aspirin per patient
was 8000 mg.
Overall, the AE incidences were comparable between
the aspirin (10.9 %) and placebo groups (12.4 %) [OR:
0.86 (95 % confidence interval [CI] 0.56, 1.34); RD: -1.49
(95 % CI -6.01, 3.03)]. Reported events were mostly mild
to moderate in nature (Table 3). One serious AE occurred
in the aspirin group (non-cardiac chest pain), but this was
determined to be unrelated to study drug. One patient, also
in the aspirin group, discontinued treatment due to a skin
rash that developed following 3 days of aspirin therapy and
which was therefore classified as an adverse drug reaction.
Gastrointestinal AEs were more common in subjects
treated with aspirin (7.4 %) than placebo (5.4 %). Though
this difference did not meet statistical significance, a trend
towards higher risk was observed with aspirin use com-
pared with placebo [OR: 1.41 (95 % CI 0.78, 2.54); RD:
2.00 (95 % CI -1.35, 5.35)]. The gastrointestinal PTs
Table 1 Characteristics of the studies included in the meta-analysis
Characteristic Study 1 Study 2 Study 3
Study design Randomized, double-blind,
placebo-controlled, parallel
Randomized, double-blind,
placebo-controlled, parallel
Randomized, double-blind, placebo-controlled,
parallel
Clinical phase III III III
Number of
centers
68 12 1
Countries Italy, Poland, Slovakia, and
USA
Germany and UK UK
Indication Acute sore throat Acute lower back pain Acute sore throat and/or headache
Dosage 1000 mg tid for 3 days; daily
dose 3000 mg
1000 mg tid prn for 5 days; daily
dose 3000 mg maximum
1000 mg bid or tid on day 1 and 1000 mg tid on
days 2 and 3; daily dose 3000 mg maximum
Treatment arms
(safety set)
Aspirin (n = 250)
Placebo (n = 262)
Aspirin/pseudoephedrine
(n = 253)
Pseudoephedrine (n = 251)
Aspirin (n = 112)
Placebo (n = 116)
Ibuprofen (n = 109)
Aspirin (n = 240)
Placebo (n = 121)
Aspirin/pseudoephedrine (n = 235)
Pseudoephedrine (n = 237)
Patients included
in the analysis
Aspirin (n = 149)
Placebo (n = 196)
Aspirin (n = 54)
Placebo (n = 69)
Aspirin (n = 230)
Placebo (n = 121)
Subject sex Male: 44 %
Female: 56 %
Male: 53 %
Female: 47 %
Male: 29 %
Female: 71 %
Age (years)
Mean (range) 36.6 (18–65) 46.0 (17–81) 20.1 (18–39)
Median 35.0 46.0 20.0
bid twice daily, prn as needed, tid three times daily
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heartburn, nausea, vomiting, and abdominal pain are of
major importance for the tolerability of aspirin [5, 6]. The
incidence of their combination was higher in the aspirin
group than in the placebo group (6.2 vs. 4.4 %), but dif-
ferences did not reach statistical significance. However,
there was again a trend towards an increased risk for
aspirin [OR: 1.43 (95 % CI 0.76, 2.73); RD: 1.78 (95 % CI
-1.33, 4.89)]. The same higher incidence in the aspirin
group was observed for the PT dyspepsia (aspirin 1.2 %,
placebo 0.3 %), but it had a high OR (5.14) with a very
Table 2 Subject demographics
of the study population
Demographic Aspirin (N = 433) Placebo (N = 386) Total (N = 819)
Sex [n (%)]
Men 151 (34.9) 167 (43.3) 318 (38.8)
Women 282 (65.1) 219 (56.7) 501 (61.2)
Race [n (%)]
Caucasian 423 (97.7) 375 (97.2) 798 (97.4)
Black 1 (0.2) 2 (0.5) 3 (0.4)
Asian 6 (1.4) 5 (1.3) 11 (1.3)
Other 3 (0.7) 4 (1.0) 7 (0.9)
Age (years)
Mean (SD) 29.1 (13.16) 33.0 (14.16) 30.9 (13.76)
Range 18–81 17–77 17–81
Median 22.0 28.5 25.0
Height (cm)
Mean (SD) 169.6 (9.48) 170.6 (9.24) 170.1 (9.37)
Range 147–203 152–201 147–203
Weight (kg)
Mean (SD) 69.94 (13.57) 71.06 (13.94) 70.47 (13.75)
Range 42.0–121.4 45.0–120.0 42.0–121.4
BMI (kg/m2)
Mean (SD) 24.23 (3.806) 24.29 (3.530) 24.26 (3.676)
Range 16.8–45.1 16.5–36.2 16.5–45.1
BMI body mass index, SD standard deviation
Table 3 Incidences, odds ratios, and risk differences for adverse events
Event Response/treated Odds ratio (95 %
CI)
Risk difference (95 %
CI)
Aspirin
[N (%)]
Placebo
[N (%)]
Adverse events 47/433 (10.9) 48/386 (12.4) 0.86 (0.56, 1.34) -1.49 (-6.01, 3.03)
Mild intensity 18 (4.2) 24 (6.2) n.c. n.c.
Moderate intensity 19 (4.4) 16 (4.1) n.c. n.c.
Severe intensity 10 (2.3) 8 (2.1) n.c. n.c.
Gastrointestinal adverse events 32/433 (7.4) 21/386 (5.4) 1.41 (0.78, 2.54) 2.00 (-1.35, 5.35)
Dyspepsia 5/433 (1.2) 1/386 (0.3) 5.14 (0.60, 44.25) 1.01 (-0.17, 2.19)
Combined heartburn, nausea, vomiting, and abdominal
pain
27/433 (6.2) 17/386 (4.4) 1.43 (0.76, 2.73) 1.78 (-1.33, 4.89)
Headache 6/433 (1.4) 13/386 (3.4) 0.45 (0.17, 1.23) -1.74 (-3.88, 0.41)
Dizziness 4/433 (0.9) 4/386 (1.0) 1.04 (0.26, 4.20) 0.04 (-1.40, 1.49)
Tinnitus 3/203 (1.5) 0/265 (0.0) 36.10 (0.10, 13,705) 1.48 (-0.18, 3.13)
Abdominal pain 3/379 (0.8) 2/317 (0.6) 1.71 (0.27, 10.82) 0.38 (-0.89, 1.64)
CI confidence interval; n.c. not calculated
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broad 95 % CI (0.60, 44.25), indicating little precision due
to a limited number of events. Incidences and ORs calcu-
lated for headache, dizziness, tinnitus, and abdominal pain
showed no additional risk associated with aspirin compared
with placebo (Table 3). There were no reports of serious
gastrointestinal complications such as perforations, ulcers,
and bleeding, as was the case with impaired hearing ability,
mental confusion, cerebral hemorrhage, and hypersensi-
tivity reactions.
4 Discussion
The findings from the current individual patient data meta-
analysis appear to support the safety and tolerability of the
use of multiple high-dose treatment with aspirin in the self-
medication setting for the acute treatment of pain, fever, or
the common cold in an otherwise healthy and young pop-
ulation. Aspirin use was not associated with a significant
increase in the risk of overall or gastrointestinal-specific
AEs. In fact, ORs and RDs for the comparison of aspirin
and placebo were not statistically significant for any of the
safety endpoints. Gastrointestinal AEs occurred at a low
rate overall, and, importantly, no cases of serious gas-
trointestinal complications (i.e., perforation, ulceration, or
bleeding) were reported. However, the generalizability of
these findings to a broader population is inappropriate as
the data used for this meta-analysis were sourced from a
limited pool of qualifying Bayer-sponsored studies, which
comprised healthy, younger adult subjects at low risk of
gastrointestinal events. This could have contributed to the
low incidence of gastrointestinal AEs observed in both
treatment groups.
This multiple-dose meta-analysis enhances the existing
safety profile of OTC aspirin used for non-cardiac indica-
tions, as the large majority of existing data are derived
from very short-term, mostly single-dose studies. It must be
emphasized, however, that though the doses and durations
of aspirin treatment included in this study extend beyond
single-dose administration, they still reflect short-term
treatment in the OTC setting. Therefore, conclusions drawn
from these data are not valid in the context of long-term
use, or use that lies outside of the treatment algorithms
outlined in these studies.
The results of the current analysis are generally in
agreement with findings from four previous meta-analyses
and one randomized controlled clinical trial examining the
safety of acute OTC aspirin use. Meta-analyses by Lanas
et al. [5], Edwards et al. [7], and Steiner and Voelker [8]
consisted mostly of single-dose data, while the current
analysis, Baron et al. [6], and the PAIN [Paracetamol,
Aspirin and Ibuprofen New tolerability] study [9] exam-
ined higher OTC doses used for a longer duration
(3–10 days). In order to bring the current data into per-
spective, Table 4 shows the incidences, ORs, RDs, and
relative risks of overall and gastrointestinal AEs.
Among the meta-analyses, the incidence of aspirin
versus placebo AEs is consistently in the range of
10–15 %, and the AEs reported in the current analysis were
comparable between the aspirin and placebo groups (10.9
vs. 12.4 %). Lanas et al. [5] observed a similar pattern
(15.2 vs. 15.5 %), although these AE rates appear to be
higher than those seen in our study. This could be due, in
part, to the substantially larger population in the Lanas
et al. [5] analysis. The Edwards et al. [7] and Steiner and
Voelker [8] analyses reported AE incidences within a
similar range (13 vs. 11 % and 14.9 vs. 11.1 %, respec-
tively) to those seen in Lanas et al. [5] and the current
study.
The incidence of gastrointestinal AEs is generally in the
range of 6–10 % for aspirin (including the PAIN study) and
4–9 % for placebo, showing a substantial overlap of the
two ranges. The incidence of gastrointestinal AEs was
higher in the aspirin than in the placebo group (7.4 vs.
5.4 %) in the current analysis, a pattern also seen in the
study by Lanas et al. [5] (9.9 vs. 9.0 %), although the
increase in risk was significant in that study (OR 1.3; 95 %
CI 1.1, 1.5). The Baron et al. [6] meta-analysis also
observed a higher incidence of overall gastrointestinal risk
with aspirin use than with placebo, but reported no serious
AEs.
The AE of interest, dyspepsia, was associated with an
OR of 5.14 in the current study. However, there is a very
wide CI associated with this estimate (0.6, 44), suggesting
a substantial level of variability in the data due to the low
number of cases (sparse data scenario), but also a trend
towards significance due to the large right shift of the CI.
Yet, upon examining the data from the Lanas et al. [5]
analysis, it becomes apparent that this finding in our study
should not be disregarded: Lanas et al. [5] found a signif-
icantly higher risk of dyspepsia in patients taking aspirin.
Again, the difference in population size could have con-
tributed to the discrepancy in the results observed for these
two studies.
Taken together, these results suggest that the safety
and tolerability seen with short-term OTC aspirin (used
according to the directions on the label) extends to
multiple-day use (not to exceed 3–10 days depending on
local country regulations and indication) in a population
with low gastrointestinal risk. It must be noted, however,
that this observation may not apply to higher-risk
patients such as the elderly or those with a history of
ulcers, and is only representative of an acute clinical
scenario appropriate for self-treatment. No previously
unknown risks, which would change the overall benefit–
risk ratio of aspirin for pain and fever, have been
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detected in the current or previous analyses and studies.
Furthermore, serious AEs such as perforations, ulcers,
and bleeding have not been observed in these clinical
investigations.
The frequency of AEs was quite low in the current
analysis and the meta-analyses discussed here. This may in
part be due to the population studied, as subjects were
typically young and otherwise healthy. This probably does
not mirror the patient populations from several observa-
tional studies that have suggested that aspirin taken for
pain, fever, or the common cold is associated with an
increased risk of major gastrointestinal complications,
similar to other non-selective NSAIDs [10–12]. A recent
large population-based study found that those on pre-
scription NSAIDs were generally older, more frequently
overweight, and had more co-morbidities than their OTC
NSAID-using counterparts [3]. While there is a well-
known association between long-term NSAID use, the
above-mentioned risk factors, and an increased likelihood
of developing serious gastrointestinal complications, cau-
tion must be exercised in drawing generalized conclusions
from data obtained specifically from OTC or prescription-
strength NSAID use, as these data may not be applicable to
a broader or disparate population.
Table 4 Comparison of studies investigating the safety and tolerability of aspirin
Current meta-
analysis
Lanas et al. [5]
meta-analysis
Edwards et al.
[7] meta-
analysis
Steiner and Voelker
[8] meta-analysis
Baron et al. [6]
meta-analysis
PAIN study RCT
[9]
Year 2015 2011 1999 2009 2013 1999
Number of
studies/patients
3/819 67/13,222 72/6550 9/2852 78/19,829 8633 patients
Patient
population
included
Patients with
symptomatic upper
respiratory tract
infection or acute
lower back pain
Patients with
pain, fever,
or common
cold
Patients with
post-
operative
pain
Patients with acute
migraine attacks,
episodic tension-
type headache,
and dental pain
Patients on ASA
who experienced a
GI event
Patients with
common mild to
moderate pain
Treatments Daily ASA dose of
2000 mg taken for
a minimum
duration of 3 days
and up to 6 days
Mostly single
ASA doses of
C325 mg/day
Single-dose
ASA
600/650,
1000, or
1200 mg
Single doses of ASA
1000 mg
ASA dose between
325 and
4000 mg/day with
a treatment
duration of up to
10 days
ASA up to 3 g/day,
PAR up to
3 g/day, or IBU
up to 1.2 g/day
for up to 7 days
Safety endpoint Patient-reported AEs Patient-
reported AEs
Patient-
reported
AEs
Patient-reported
AEs
Patient-reported
AEs
Patient-reported
AEs
Results [95 % CI]
All AEs ASA 10.9 %
Placebo 12.4 %
OR 0.86 [0.56, 1.34]
RD -1.49 [-6.01,
3.03]
ASA 15.2 %
Placebo
15.5 %
OR 1.1 [0.96,
1.2]
RD 1.0 [-0.5,
2.5]
ASA all doses
12.0 %
Placebo
10.0 %
RR 1.3 [0.9,
1.5]
ASA 600/650
mg 13.0 %
Placebo
11.0 %
RR 1.2 [1.03,
1.4]
ASA 14.9 %
Placebo 11.1 %
RR 1.3 [1.1, 1.6]
Not available ASA 18.5 %
IBU 13.4 %
PAR 13.8 %
GI AEs ASA 7.4 %
Placebo 5.4 %
OR 1.41 [0.78, 2.54]
RD 2.00 [-1.35,
5.35]
ASA 9.9 %
Placebo 9.0 %
OR 1.3 [1.1,
1.5]
RD 2.1 [0.9,
3.3]
ASA
600/650 mg
3.7 %
Placebo 1.1 %
RR 2.5 [1.2,
5.1]
ASA 5.9 %
Placebo 3.5 %
RR 1.7 [1.2, 2.4]
ASA 9.4 %
Placebo 4.2 %
OR 2.12 [0.95, 4.76]
ASA 7.1 %
IBU 4.0 %
PAR 5.3 %
AEs adverse events, ASA aspirin, CI confidence interval, GI gastrointestinal, IBU ibuprofen, OR odds ratio, PAR paracetamol, RCT randomized
controlled trial, RD risk difference, RR relative risk
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ORs and RDs for the comparison of aspirin and placebo
were not statistically significant for any of the safety end-
points of interest. However, interpretation of these results
must be accompanied by a thorough inspection of the
limitations of the analysis. First, the analysis population
was young and generally healthy. Furthermore, the total
sample size is limited. A low number of events may have
impaired the sensitivity of the analysis to detect a differ-
ence between aspirin and placebo. In this situation, a lack
of statistical significance should not be considered syn-
onymous with the conclusion that aspirin does not increase
the risk of gastrointestinal AEs, particularly for endpoints
for which other studies have shown a trend for such an
association. The studies included in the analysis did not
prohibit the use of gastroprotective agents, though con-
comitant medications were documented and subjects were
generally healthy.
5 Conclusions
This analysis shows that OTC aspirin taken at doses of
2500–3000 mg/day over 3–6 days is well-tolerated when
taken as directed for the treatment of acute pain, fever, and
the common cold. Though the incidence of gastrointestinal
AEs was elevated in aspirin users compared with placebo
users, the risk of these AEs was not statistically signifi-
cantly different, and there were no reports of serious gas-
trointestinal complications in either of the groups.
However, it is critical that the results of this study should
be interpreted within the full context of the limited sample
size. Therefore, firm conclusions cannot be drawn based on
these data alone.
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